Follow us on Twitter
twitter icon@FreshPatents


Rheumatoid Arthritis patents

      

This page is updated frequently with new Rheumatoid Arthritis-related patent applications.




 Compositions and methods of use for therapeutic antibodies patent thumbnailnew patent Compositions and methods of use for therapeutic antibodies
The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
Novartis Ag


 Compositions and methods for immunomodulation in an organism patent thumbnailnew patent Compositions and methods for immunomodulation in an organism
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut


 Compositions and methods of treating lupus nephritis patent thumbnailnew patent Compositions and methods of treating lupus nephritis
The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type ii anti-cd20 antibody.
Genentech, Inc.


 Methods, agents and compositions for treatment of inflammatory conditions patent thumbnailnew patent Methods, agents and compositions for treatment of inflammatory conditions
The present invention relates to the screening, diagnosis, prognostic evaluation, and treatment or prevention of age associated inflammation, chronic inflammation, and inflammatory diseases. In particular, the present invention relates to treating or preventing inflammatory diseases (e.g.
Betanien Hospital


 Triazolone compounds as mpges-1 inhibitors patent thumbnailTriazolone compounds as mpges-1 inhibitors
The present disclosure is directed to compounds of formula (i), and pharmaceutically acceptable salts thereof, as mpges-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin e synthase-1 (mpges-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases..
Glenmark Pharmaceuticals S.a.


 Baff selective binding compounds and related methods patent thumbnailBaff selective binding compounds and related methods
The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Ossianix, Inc.


 Compositions and methods for immunomodulation in an organism patent thumbnailCompositions and methods for immunomodulation in an organism
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12)or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut


 Novel peptidomimetics with antiangiogenic activity patent thumbnailNovel peptidomimetics with antiangiogenic activity
We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (armd), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.. .
Uniwersytet Warszawski (heir Of The Deseased Inventor)


 Heterocyclic compounds and their uses patent thumbnailHeterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.


 4-substituted pyrrolo[2,3-d]pyrimidine compound and use thereof patent thumbnail4-substituted pyrrolo[2,3-d]pyrimidine compound and use thereof
The activity experimental results of the invention show that the new compound has obvious effect and activity in inhibition of janus kinases, jak-stat, cell proliferation of human lymphocytoma, and rheumatoid arthritis.. .

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis..
Five Prime Therapeutics, Inc.

Tnfa-il-17 bispecific antibodies

Bispecific tetravalent antibodies against il-17 and tnfa, useful in therapy, e.g. The treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions..
Hoffmann-la Roche Inc.

Bicyclic heteroaryl indole analogues useful as ror gamma modulators

The present disclosure is directed to compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein x, x1, m, r2, r3, r4, r5, m, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (rorγt). These compounds prevent, inhibit, or suppress the action of rorγt and are therefore useful in the treatment of rorγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, copd, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases and cancer..
Glenmark Pharmaceuticals S.a.

Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods.
Curelab Oncology, Inc.

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis..
Five Prime Therapeutics, Inc.

Tetrahydro-tetrazolo[1,5-a]pyrazines as ror-gamma inhibitors

The present invention relates to tetrahydro-tetrazolo[1,5-a]pyrazine compounds of formula (i), wherein r1 denotes —r3, —ch2—r3 or —co—r3; r2 denotes ar2, hetar2 or c3-7-cycloalkyl; and r3 denotes ar3, hetar3 or c3-7-cycloalkyl. These compounds are useful for inhibiting the retinoid-related orphan receptor γ (ror γ, ror-gamma) and for the prevention and/or treatment of medical conditions affected by ror γ activity such as rheumatoid arthritis, multiple sclerosis, psoriasis, ulcerative colitis, asthma, autoimmune hepatitis or type 1 and type 2 diabetes..
Merck Patent Gmbh

Wnt pathway modulators

The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula i, defined herein, as wnt pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by wnt pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula i are also provided..
Agency For Science, Technolgy And Research

Uses of kappa opioid synthetic peptide amides

The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.

Novel compounds as jnk kinase inhibitors

The present invention is directed to modulators, such as inhibitors, of jnk isoform 2 (jnk2) or isoform 3 (jnk3) comprising compounds of formula (i) or formula (ii) as described herein. Compounds of the invention can be used for treatment of a medical disorder in a patient wherein modulation of jnk3 is medically indicated, such as when the disorder is parkinson disease (pd) alzheimer's disease (ad), huntington's disease (hd), amyotrophic lateral sclerosis (als), multiple sclerosis (ms), myocardial infarction (mi), glaucoma, obesity, diabetes, cancer, rheumatoid arthritis, fibrotic disease, pulmonary fibrosis, kidney disease, liver inflammation, crohns disease, hearing loss, prader willi syndrome, or a condition where modification of feeding behavior is medically indicated..
The Scripps Research Institute

Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same

The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (hdac) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (hdac) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases..
Chong Kun Dang Pharmaceutical Corp.

Ebna1 inhibitors and their use

The invention provides ebna1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by ebna1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent epstein-barr virus (ebv) infection.
The Wistar Institute Of Anatomy And Biology

Compositions for the treatment of rheumatoid arthritis and methods of using same

The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody that specifically binds human interleukin-6 receptor (hil-6r).. .
Regeneron Pharmaceuticals, Inc.

Il-17 antibody formulation

The present invention provides stabilized pharmaceutical formulations for anti-il-17 antibodies, comprising e.g. Citrate, sodium chloride and polysorbate-80 at ph 5.7.
Eli Lilly And Company

Uses and compositions for treatment of juvenile rheumatoid arthritis

The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (jra). The invention describes methods and uses for treating jra, wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof, is used to prevent flare-ups associated with jra.
Abbvie Biotechnology, Ltd.

Cyclic citrullinated peptide, rheumatoid arthritis diagnosis composition including the same, rheumatoid arthritis diagnosis method using the peptide or the composition, and method of screening diagnostic marker for rheumatoid arthritis

rheumatoid arthritis is efficiently diagnosed with improved patient's convenience using a rheumatoid arthritis diagnosis composition and a kit, each including cyclic citrullinated peptide (ccp), a rheumatoid arthritis diagnosis method using the ccp, the rheumatoid arthritis diagnosis composition, or the kit, a method of obtaining information for rheumatoid arthritis diagnosis, and a method of screening a novel diagnostic marker for rheumatoid arthritis.. .
Korea Institute Of Science And Technology

Inhibitors of bruton's tyrosine kinase

This application discloses compounds according to generic formula i: wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.

Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors

Compounds of formula i are provided, which are jak inhibitors and are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
Merck Sharp & Dohme Corp.

Phenyl linked quinolinyl modulators of rorgammat

The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

Biomarker for rheumatoid arthritis diagnosis or activity evaluation

The present invention relates to a composition and kit for rheumatoid arthritis diagnosis or activity evaluation, the composition and kit each including an agent for measuring the concentration of at least one protein selected from a group consisting of soluble cd14 (scd14), a-1-acid glycoprotein 1 (agp1), and a-1-acid glycoprotein 2 (agp2). Further, the present invention relates to a use of the composition for diagnosing rheumatoid arthritis or evaluating activity..
Catholic University Industry-academic Cooperation Foundation

Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease

An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf.
Thymon, Llc

High concentration formulations of anti-c5 antibodies

The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component c5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions.
Alexion Pharmaceuticals, Inc.

Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors

The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
Merck Sharp & Dohme Corp.

Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors

The instant invention provides compounds of formula (i) which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
Merck Sharp & Dohme Corp.

Biological markers and methods for predicting response to b-cell antagonists

Biological markers that predict patient responsiveness to b-cell antagonists are provided. Also provided are methods of using such biological markers.
Genentech, Inc.

Nucleic acids encodng anti-c5a antibodies

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. .
Alexion Pharmaceuticals, Inc.

Novel scorpion toxin analogue and treating autoimmune diseases

A novel peptide analogue of the heterometrus spinnifer toxin hstx1 is disclosed along with its application as, for example, a therapeutic agent for treating an autoimmune disease such as multiple sclerosis (ms) or rheumatoid arthritis (ra). The analogue comprises a peptide with an amino acid substitution at amino acid position 14 of the wild-type (wt) peptide sequence (or a position corresponding to position 14 of the wt peptide sequence).
Baylor College Of Medicine

Treatment methods for rheumatoid arthritis

The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein.

Antibody therapeutics that bind jag1

There is disclosed compositions and methods relating to or derived from anti-jag1 antibodies. More specifically, there is disclosed fully human antibodies that bind jag1, jag1-binding fragments and derivatives of such antibodies, and jag1-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Anti-baff-anti-il-17 bispecific antibodies

Bispecific antibodies are provided that specifically bind b-cell activating factor of the tnf family (baff) and interleukin-17a (il-17) and are characterized as having high affinity and strong neutralizing properties to both baff and il-17. The bispecific antibodies of the invention are expected to be useful in treating lupus nephritis (ln), systemic lupus erythematosus (sle), rheumatoid arthritis (ra), psoriasis (ps), ankylosing spondylitis (as), psoriatic arthritis (pa), primary sjögren's syndrome (pss), or multiple myeloma (mm)..
Eli Lilly And Company

Novel 8-oxoprotoberberine derivative or pharmaceutically acceptable salt thereof, preparation method therefor and pharmaceutical composition for preventing or treating diseases associated with activity of nfat5, containing same as active ingredient

The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of nfat5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of nfat5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of nfat5 and the secretion of inflammatory cytokines and reduces the expression of naft5 in mice with rheumatoid arthritis by directly inhibiting the transcription of nft5..
The Catholic University Of Korea Industry-academic Cooperation Foundation

Orexin-control of bone formation and loss

The use of orexin 1 receptor antagonists and/or orexin 2 receptor agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases..
The Board Of Regents Of The University Of Texas System

Heteroaryl syk inhibitors

The invention relates to new substituted heteroaryls of formula (1), wherein a is selected from the group consisting of n and ch, d is ch, e is selected from the group consisting of c and n, t is c, g is selected from the group consisting of c and n, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein r1, m and r3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. .
Boehringer Ingelheim International Gmbh

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders.

The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis, lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.

Puma protein expression vector and use thereof in gene therapy

The present invention relates to a viral vector for expression of the cell death-inducing puma protein, for use in gene therapy, for example for the treatment of rheumatoid arthritis. This vector consists in particular of a recombinant adenovirus expressing the gene encoding the puma protein and of a recombinant baculovirus containing a coxsackie-adenovirus receptor (car)..
Institut National De La Sante Et De La Recherche Medicale (inserm)

Polysialic acid-polycaprolactone micelles for drug delivery

Psa-pcl micelles were developed as carrier systems for pharmaceutical drugs. As an example, cyclosporine a (cya) was encapsulated in the micelles and physical characterization, including size and zeta potential, demonstrated that the micelles possess favorable properties for drug delivery.
Syracuse University

Antagonist anti-il-7 receptor antibodies and methods

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (il-7r). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids.
Rinat Neuroscience Corp.

Use of gelsolin to diagnose and treat inflammatory diseases

The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).. .
The Brigham And Women's Hospital, Inc.

Causative agents and diagnostic methods relating to rheumatoid arthritis

Methods, reagents and compositions thereof for predicting ra onset in susceptible individuals, diagnosing ra onset, and/or evaluating efficacy of a therapeutic regimen for treating ra are described herein. Determining the amount of a particular bacterial species comprising seq id no: 1, seq id no: 2, or seq id no: 3 (seq id no: 1+bacteria) serves as a biomarker for the above indications..

Combination of lupeol acetate and curcumin used for the treatment or prevention of activated osteoclast precursor associated disorders

The present invention relates to synergistic combinations of lupeol acetate and curcumin at low dosage, and their use for the treatment or prevention of activated osteoclast precursor related diseases, including rheumatoid arthritis and osteoporosis.. .
National Yang-ming University



Rheumatoid Arthritis topics:
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Autoimmune
  • Multiple Sclerosis
  • Immune Disease
  • Autoimmune Disease
  • Antibodies
  • Astaxanthin
  • Hyaluronate
  • Hyaluronic Acid
  • Joint Pain
  • Hyaluronan
  • Immune Diseases
  • Autoimmune Diseases
  • Lung Cancer


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.9351

    file did exist - 2871

    1 - 1 - 51